30% increase in R&D projects for neglected diseases in 2014; report

24 February 2015

Trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has released the 2014 Status Report on pharmaceutical R&D projects to address neglected diseases, showing there has been a 30% increase in such work.

The report lists 186 R&D projects supported by IFPMA members to develop new or improved medicines and vaccines for 11 neglected conditionsthat each year kill or disable millions of people in low- and middle-income countries. Of the 186 treatments or vaccines R&D projects, 28 are undergoing early stage clinical trials, while 10 currently go through the final stages of demonstrating their efficacy, quality and safety.

The 10 more imminent breakthroughs concern tuberculosis (TB; three projects), malaria (five projects), dengue (one project), and intestinal worms (one project), nearing the end of what is on average a 10 to 15 years R&D process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >